

ASX RELEASE

12 May 2026

Notice under Section 708A(5)(e) of the Corporations Act

Amplia Therapeutics Limited (“ATX” or “the Company”) has today issued a total of 240,385 fully paid ordinary shares (**Shares**) pursuant to the exercise of Zero Exercise Price Options. The Options were issued to the Company’s Chief Medical Officer under the Company’s Equity Incentive Plan.

All of the Shares issued will rank pari passu with existing ATX ordinary shares.

The Company gives notice under section 708A (5)(e) of the Corporations Act 2001 (**Act**) that:

- the Company has issued 240,385 Shares without disclosure to investors under Part 6D.2 of the Act;
- as at the date of this notice, the Company has complied with:
 - the provisions of Chapter 2M of the Act as they apply to the Company; and
 - sections 674 and 674A of the Act; and
- as at the date of this notice there is no excluded information (within the meaning of sections 708A (7) and 708A(8) of the Act) which is required to be disclosed by the Company.

- End -

This ASX announcement was approved and authorised for release by the Company Secretary.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn.